PLoS ONE (Jan 2019)

Stereotactic body radiation therapy for locally advanced pancreatic cancer.

  • Jinhong Jung,
  • Sang Min Yoon,
  • Jin-Hong Park,
  • Dong-Wan Seo,
  • Sang Soo Lee,
  • Myung-Hwan Kim,
  • Sung Koo Lee,
  • Do Hyun Park,
  • Tae Jun Song,
  • Baek-Yeol Ryoo,
  • Heung-Moon Chang,
  • Kyu-Pyo Kim,
  • Changhoon Yoo,
  • Jae Ho Jeong,
  • Song Cheol Kim,
  • Dae Wook Hwang,
  • Jae Hoon Lee,
  • Ki Byung Song,
  • Yoon Young Jo,
  • Jongmoo Park,
  • Jong Hoon Kim

DOI
https://doi.org/10.1371/journal.pone.0214970
Journal volume & issue
Vol. 14, no. 4
p. e0214970

Abstract

Read online

PurposeStereotactic body radiation therapy (SBRT) is a promising treatment modality for locally advanced pancreatic cancer (LAPC). We evaluated the clinical outcomes of SBRT in patients with LAPC.Patients and methodsWe retrospectively analyzed the medical records of patients with LAPC who underwent SBRT at our institution between April 2011 and July 2016. Fiducial markers were implanted using endoscopic ultrasound guidance one week prior to 4-dimensional computed tomography (CT) simulation and daily cone beam CT was used for image guidance. Patients received volumetric modulated arc therapy or intensity modulated radiotherapy using respiratory gating technique. A median dose of 28 Gy (range, 24-36 Gy) was given over four consecutive fractions delivered within one week. Survival outcomes including freedom from local disease progression (FFLP), progression-free survival (PFS), and overall survival (OS) were analyzed. Acute and late toxicities related to SBRT were assessed.ResultsA total of 95 patients with LAPC were analyzed, 52 of which (54.7%) had pancreatic head cancers. Most (94.7%) had received gemcitabine-based chemotherapy. The 1-year FFLP rate was 80.1%. Median OS and PFS were 16.7 months and 10.2 months, respectively; the 1-year OS and PFS rates were 67.4% and 42.9%, respectively. Among 79 patients who experienced failure, the sites of first failures were isolated local progressions in 12 patients (15.2%), distant metastasis in 55 patients (69.6%), and both in 12 patients (15.2%). Seven patients (7.4%) were able to undergo surgical resection after SBRT and four had margin-negative resections. Three patients (3.2%) had grade 3 nausea/vomiting during SBRT, and late grade 3 toxicity was observed in another three patients.ConclusionsLAPC patients who received chemotherapy and SBRT had favorable FFLP and OS with minimal treatment-related toxicity. The most common pattern of failure was distant metastasis, which warrants further studies on the optimal scheme of chemotherapy and SBRT.